NasdaqGS:CNTABiotechs
Centessa Pharmaceuticals (CNTA): Rapid 74.3% Revenue Growth Challenges Profitability Concerns
Centessa Pharmaceuticals (CNTA) is forecast to deliver stellar annual revenue growth of 74.3%, far surpassing the broader US market’s 10.5% pace. Despite the robust top-line outlook, the company remains unprofitable and is expected to continue operating at a loss over the next three years. While losses have narrowed at an average rate of 4.3% per year over the past five years, there are no signs of an imminent shift toward profitability. This raises the stakes for investors weighing rapid...